Stockscreener 앱 받기
52.74
0.37%
0.08
전일 마감가:
$52.66
열려 있는:
$52.6
하루 거래량:
83,899
Relative Volume:
0.17
시가총액:
$3.35B
수익:
-
순이익/손실:
$-145.21M
주가수익비율:
-22.93
EPS:
-2.3
순현금흐름:
$-140.12M
1주 성능:
-5.02%
1개월 성능:
-0.44%
6개월 성능:
+25.55%
1년 성능:
+6.80%
1일 변동 폭
$52.02
$53.10
1주일 범위
$52.02
$56.00
52주 변동 폭
$31.42
$58.26
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Company Profile
명칭
Moonlake Immunotherapeutics
전화
41 41 510 8022
주소
DORFSTRASSE 29, ZUG
MLTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
52.76 | 3.41B | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.54 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
462.68 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.87 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
654.91 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.13 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-28 | 개시 | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-11-05 | 재개 | Wedbush | Outperform |
| 2024-08-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-11-02 | 개시 | Stifel | Buy |
| 2023-09-14 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 개시 | Needham | Buy |
| 2023-06-15 | 개시 | Barclays | Equal Weight |
| 2023-05-01 | 개시 | Guggenheim | Buy |
| 2023-03-22 | 개시 | Wedbush | Outperform |
| 2023-03-09 | 개시 | BTIG Research | Buy |
| 2023-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 개시 | Bryan Garnier | Buy |
| 2022-11-11 | 개시 | Jefferies | Buy |
| 2022-08-25 | 개시 | SVB Leerink | Outperform |
| 2022-07-21 | 개시 | H.C. Wainwright | Buy |
| 2022-07-07 | 개시 | Cowen | Outperform |
모두보기
문레이크 이뮤노테라퓨틱스 주식(MLTX)의 최신 뉴스
MoonLake Immunotherapeutics Shows Early Signs of Technical StrengthJuly 2025 Drop Watch & AI Enhanced Market Trend Forecasts - beatles.ru
Does MoonLake Immunotherapeutics have pricing powerWall Street Watch & High Accuracy Trade Signal Alerts - thegnnews.com
I'm Over the Moon About This Promising Biotech - TheStreet Pro
Ranking MoonLake Immunotherapeutics among high performing stocks via toolsPrice Action & AI Driven Stock Movement Reports - Newser
Real time social sentiment graph for MoonLake ImmunotherapeuticsInsider Buying & Stock Portfolio Risk Control - Newser
MoonLake Immunotherapeutics: A High-Conviction Speculative Play on Sonelokimab's Transformative Potential - AInvest
MoonLake Immunotherapeutics (MLTX): A Bull Case Theory - MSN
What data driven models say about MoonLake Immunotherapeutics’s futureQuarterly Risk Review & Daily Risk Controlled Trade Plans - Newser
When is the best time to exit MoonLake ImmunotherapeuticsJuly 2025 Fed Impact & Growth Focused Entry Point Reports - Newser
MoonLake Immunotherapeutics stock trend outlook and recovery path2025 Volatility Report & Safe Capital Growth Plans - Newser
MoonLake Immunotherapeutics Company’s Quarterly Earnings Growth: What the Numbers SayJuly 2025 Fed Impact & AI Powered Market Entry Strategies - Newser
Should you hold or exit MoonLake Immunotherapeutics now2025 Dividend Review & Daily Chart Pattern Signal Reports - Newser
Sector ETF performance correlation with MoonLake ImmunotherapeuticsLong Setup & Risk Controlled Daily Trade Plans - Newser
What recovery options are there for MoonLake Immunotherapeutics2025 Technical Patterns & Free Community Supported Trade Ideas - Newser
MoonLake Immunotherapeutics stock trend forecastWeekly Stock Recap & Weekly Return Optimization Alerts - Newser
Visual analytics tools that track MoonLake Immunotherapeutics performanceJuly 2025 Outlook & Short-Term High Return Ideas - Newser
Are MoonLake Immunotherapeutics' (MLTX) Rising Losses a Sign of Strategic Investment or Mounting Pressure? - simplywall.st
Real time social sentiment graph for MoonLake Immunotherapeutics [Trade Risk Assessment]Safe Entry Zone Identification - Newser
Using Python tools to backtest MoonLake Immunotherapeutics strategies [July 2025 Macro Moves]Real-Time Volume Analysis Alerts - Newser
MoonLake Immunotherapeutics: Maintaining A Small Holding (NASDAQ:MLTX) - Seeking Alpha
MoonLake Immunotherapeutics: Robust Financials and Promising Phase 3 VELA Program Back Strong Buy Rating - AInvest
MoonLake Immunotherapeutics: Strong Buy Rating Amid Promising Phase 3 VELA Program and Robust Financial Position - TipRanks
Does Rising Loss at MoonLake Immunotherapeutics (MLTX) Signal Strategic Investment or Expense Control Challenges? - simplywall.st
Rising Losses Might Change the Case for Investing in MoonLake Immunotherapeutics (MLTX) - simplywall.st
Wedbush Has Negative Forecast for MLTX Q3 Earnings - Defense World
Intraday Charts Show Spike in MoonLake Immunotherapeutics ActivitySwing Trade Entry With Volume Triggers Released - beatles.ru
Leerink Partners Maintains Buy Rating on MoonLake Immunotherapeutics with $73 Price Target - AInvest
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $66 - 富途牛牛
Goldman Sachs Boosts MoonLake Pharmaceuticals Target Price to $82, Maintains "Buy" Rating - AInvest
Clear Street Analyst Reiterates Buy Rating for MoonLake Immunotherapeutics with $108 Price Target - AInvest
MoonLake Bets Big On Its Nanobody Drug As Key Trials Approach - Finimize
MoonLake Immunotherapeutics Reports Q2 2025 Financials - TipRanks
Clear Street Initiates MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Announces Target Price $108 - 富途牛牛
MoonLake Immunotherapeutics reports Q2 EPS (87c), consensus (76c) - TipRanks
Guggenheim reiterates Buy rating on Moonlake Immunotherapeutics stock - Investing.com India
Guggenheim reiterates Buy rating on Moonlake Immunotherapeutics stock By Investing.com - Investing.com South Africa
MoonLake Immunotherapeutics: Buy Rating Driven by Promising SLK Phase 3 Data and Strong Financial Position - TipRanks
MoonLake Immunotherapeutics reports results for the quarter ended June 30Earnings Summary - TradingView
MoonLake Immunotherapeutics reports second quarter 2025 financial results and provides a business update - MarketScreener
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results And Provides A Business Update - TradingView
MoonLake Immunotherapeutics Q2 Loss Widens - MarketScreener
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update - Ariva
Earnings Flash (MLTX) MoonLake Immunotherapeutics Posts Q2 Net Loss $0.87 a Share, vs. FactSet Est of $0.68 Loss - MarketScreener
MoonLake Immunotherapeutics's Q2 net loss widens - MarketScreener
MoonLake Immunotherapeutics SEC 10-Q Report - TradingView
MoonLake Immunotherapeutics AG - Via Ritzau
How does MoonLake Immunotherapeutics compare to its industry peersDiscover stocks with explosive potential - Jammu Links News
Is it the right time to buy MoonLake Immunotherapeutics stockFree Consultation - Jammu Links News
What drives MoonLake Immunotherapeutics stock priceFree Stock Index Interpretation - Jammu Links News
How does MoonLake Immunotherapeutics generate profit in a changing economyDiscover top stock picks for aggressive growth - Jammu Links News
Is MoonLake Immunotherapeutics stock overvalued or undervaluedMaximize gains with professional stock picks - Jammu Links News
문레이크 이뮤노테라퓨틱스 (MLTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
문레이크 이뮤노테라퓨틱스 주식 (MLTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Moukheibir Catherine | Director |
Jul 03 '25 |
Sale |
48.79 |
23,500 |
1,146,565 |
0 |
1.10%
0.73%
자본화:
|
볼륨(24시간):